Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127783961 | 12778396 | 1 | I | 20160912 | 20160926 | 20160926 | EXP | US-CIPLA LTD.-2016US18425 | CIPLA | HEFFRON R, PINTYE J, MATTHEWS LT, WEBER S, MUGO N. PREP AS PERI-CONCEPTION HIV PREVENTION FOR WOMEN AND MEN. CURR HIV/AIDS REP. 2016;13:131 TO 139 | 0.00 | Y | 0.00000 | 20160926 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127783961 | 12778396 | 1 | PS | Tenofovir/Emtricitabine | EMTRICITABINETENOFOVIR | 1 | Oral | UNK, DAILY | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127783961 | 12778396 | 1 | Prophylaxis against HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127783961 | 12778396 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127783961 | 12778396 | Exposure during pregnancy | |
| 127783961 | 12778396 | Stillbirth |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |